Interim analysis of LIGHT study of Contrave (naltrexone HCl/bupropion) in CV Risk with obese patients- Orexigen/Takeda
The LIGHT Study which the FDA had asked Orexigen not to disclose (but whose results were disclosed with a new patent application) enrolled approximately 8900 patients who were treated with Contrave (naltrexone HCl/bupropion) or placebo. LIGHT study has shown in interim results that people treated with Contrave, particularly smokers and people with diabetes for less than 6 years, had a lower risk of adverse CV events than those on placebo. The risk of death was cut by 41% for patients who received Contrave.There were 24 myocardial infarctions (heart attacks) in the Contrave arm versus 34 in the placebo arm (HR=0.70; p<0.0001); seven versus 11 strokes (HR=0.63; p=0.0088); and five versus 19 cardiovascular deaths (HR=0.26; p<0.0001). A further cardiovascular outcomes trial is to proceed.
Comment: The positive interim results have to be sustained as the study proceeds and there were a high rate of discontinuations seen in the trial (62% of Contrave patients). The FDA considers that it is too early to draw conclusions from the trial.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.